for oral use Initial U.S. Approval: 2015
IRESSA is a tyrosine kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
Facts about gefitinib tablets
Approval Date: 2015
Proprietary Name: On Request
Active Ingredient(s): gefitinib tablets
Dosage Forms And Strengths: Tablets: 250 mg
Current indications: non-small cell lung cancer (NSCLC)
Medicine Approved By: – European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
Summary of FDA approved use on approval date: Click Here
(see Drugs@FDA for complete indication)
Access the best support services globally
If you have a prescription from a Registered Medical Practitioner (RMP), IPN in Delhi can assist you in obtaining access to genuine medication. Our professional will provide you with a step-by-step guide on how to legally and safely import “gefitinib tablets” based on the information you provide.
Indian Pharma Network (IPN) Legitimate consultant and facilitator in the New Delhi, India. IPN has over two decades of industry experience and extensive coverage throughout India, including major cities such as Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, the North East, Pune, and other regions.
Basement-B-5-A, Ajit Singh House Building No.12, Yusuf Sarai, South Delhi,
New Delhi:110016 India.
MOBILE / PHONE NUMBER:
M: +91 9811747774, 9891296838.
P / F: +91-11-26532129 / 26536398
Query For gefitinib tablets
Approved accessible "gefitinib tablets"
IRESSA is a prescription medicine used to treat people with non-small cell lung cancer (NSCLC) that has spread to other parts of the body and: that have certain types of abnormal epidermal growth factor receptor (EGFR) genes, and who have not had previous treatment for cancer Your healthcare provider will perform a test to make sure that IRESSA is right for you. It is not known if IRESSA is safe and effective in people with NSCLC that have other types of EGFR genes. It is not known if IRESSA is safe and effective in children.
Active ingredient: gefitinib Inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, povidone, sodium lauryl sulfate, magnesium stearate
How can 1 go about obtaining gefitinib tablets?
If gefitinib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) / +91 9811 747 774 (Mr. Neeraj).
- IRESSA (gefitinib) tablets for oral use Initial U.S. Approval: 2015
- GEFTINAT (gefitinib) tablets for oral use
- For Geftinat (gefitinib) tablets Indications And Usage, Dosage And Administration, Dosage Forms And Strengths and Drug Interactions For More Details
- Adding gefitinib to chemotherapy improves PFS in EGFR-mutant lung cancer For More Details
- Gefitinib/Chemotherapy Combo Decreases Risk of Disease Progression in EGFR+ NSCLC
Indian Pharma Network (IPN), New Delhi. India
Indian Pharma Network (IPN) is registered organisation in India, having highly qualified healthcare professionals of pharmaceutical Industry. Specialized in Oncology Products. Helped more than 6,000 patients. Registration Number : 07AAFFI2544E1ZO under GST Act.
Branch Offices in India : New Delhi | Bengaluru | Kolkata | Lucknow | Jaipur | Jodhpur.
Our Overseas Network UK | Russia | Brazil | Mexico | Germany | France| Italy | Spain | Japan | China| Australia | Brazil | Saudi Arabia | South Africa